Please login to the form below

Not currently logged in
Email:
Password:

Thai pharma market to grow 4.8 per cent

The Thai pharmaceutical market will grow at an average rate of 4.8 per cent in the medium term

The Thai pharmaceutical market will grow at an average rate of 4.8 per cent in the medium term, despite the Thai government's poor relationship with the international pharmaceutical industry.

Lax patent laws and preferential treatment of domestic producers do not protect foreign, branded drugs in the region, and a number of pharmaceutical companies are no longer distributing new drugs there.

The compulsory licensing of patented drugs by the military government in 2006 and 2007 has further compounded this problem, says the report, which adds that the government is acting within its rights and has not violated international law, as stipulated in the Trade-Related Aspects of Intellectual Property (TRIPS) agreement.

The government has offered to pay patented drug manufacturers a royalty of five per cent above the price of generics, but no compromise has been reached with the companies involved. The government has offered to pay patented drug manufacturers a royalty of five per cent above the price of generics, but no compromise has been reached with the companies involved.

Ministers have said that the compulsory licences will only apply to drugs under all public insurance schemes. Drugs bought on the open market, will not be affected by compulsory licensing. As of 2007, the Universal Healthcare Scheme covers around 48 million people, or over 70 per cent of the population.

Healthcare sector development has begun to accelerate again regarding spending and revived policies. For example, the introduction of the THB 30 universal healthcare scheme in 2001 and the new free universal healthcare scheme that started in November 2006.

The compulsory licensing of patented drugs by the military government has angered the global pharma industry, while some international charity groups have applauded the actions. The compulsory licensing affects drugs sold and distributed under all government schemes.

In 2007 alone, over 70 per cent of Thais were under the Universal Healthcare scheme. Import levels for modern drugs surpassed pre-crisis levels for the first time in 2003 and the market is still dominated by generics and OTC products.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Data desires
What are you looking to achieve with data and how are you preparing yourself to react to the results?...
The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...
Pills
Tackling antimicrobial resistance on multiple fronts
An urgent change of direction is needed in how we respond to AMR...

Infographics